A STAT and MuckRock investigation shows the NIH hasn't picked up the pace on its long Covid research. Instead, the delays have compounded.April 20, 2023Check out STAT+Sponsored By Mike Reddy for STAT The NIH has poured $1 billion into long Covid research — with little to show for it A STAT and MuckRock investigation shows the NIH hasn't picked up the pace on its long Covid research. Instead, the delays have compounded. By Rachel Cohrs and Betsy Ladyzhets STAT+ | Narcan manufacturer aims to price over-the-counter kit under $50 This form of naloxone has been used to reverse thousands of opioid overdoses. A question is whether this price will be broadly affordable. By Lev Facher Biden to tap head of National Cancer Institute to lead NIH Monica Bertagnolli, director of the National Cancer Institute, would be NIH's first permanent director since Francis Collins stepped down. By Sarah Owermohle Adobe Suspected suicide attempts surged among youth during pandemic, study shows The largest surge was among the youngest in the age groups examined — 10- to 12-year-olds and 13- to 15-year-olds. By Ambar Castillo STAT+ | The high hopes — and high stakes — behind Microsoft and Epic's plan to use AI to answer patient questions The pilot program is among the first attempts to harness generative AI to streamline the sprawling bureaucracy that surrounds health care. By Brittany Trang and Casey Ross Opinion: Judicial overreach is an immediate hazard to already precarious public health Some courts seem intent on disrupting access to critical services like mifepristone and preventive health care By Ellen J. MacKenzie and Joanne Rosen © AACR/Scott Morgan 2023 Stock drama, cancer vaccine success, and new science — highlights from AACR At the American Association for Cancer Research meeting, stocks crashed, companies debuted compounds, and a mystery got less mysterious. By Angus Chen Listen: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters This episode, we dive into the long history of a polarizing gene therapy from Sarepta Therapeutics that promises to change patients' lives. By Damian Garde and Meg Tirrell and Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments